Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc. operates in various business sectors.
Aldeyra Therapeutics Inc. (137) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.135x
Based on the latest financial reports, Aldeyra Therapeutics Inc. (137) has a cash flow conversion efficiency ratio of -0.135x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-13.22 Million) by net assets (€98.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aldeyra Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2018–2023)
This chart illustrates how Aldeyra Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aldeyra Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aldeyra Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bowen Acquisition Corp Rights
NASDAQ:BOWNR
|
N/A |
|
OKASAN SEC GRP
MU:OKN
|
N/A |
|
CARRARO
NSE:CARRARO
|
N/A |
|
VCI Global Limited Ordinary Share
NASDAQ:VCIG
|
0.154x |
|
PFERDEWETTEN AG
STU:EMH1
|
-0.669x |
|
INZI Controls Co. Ltd.
KQ:023800
|
N/A |
|
TANZANIA CIGARETTE CO. LTD
DSE:TCC
|
N/A |
|
FS Credit Opportunities Corp.
NYSE:FSCO
|
N/A |
Annual Cash Flow Conversion Efficiency for Aldeyra Therapeutics Inc. (2018–2023)
The table below shows the annual cash flow conversion efficiency of Aldeyra Therapeutics Inc. from 2018 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €119.80 Million | €-30.33 Million | -0.253x | +32.50% |
| 2022-12-31 | €151.01 Million | €-56.64 Million | -0.375x | -81.32% |
| 2021-12-31 | €205.74 Million | €-42.56 Million | -0.207x | +67.17% |
| 2020-12-31 | €59.51 Million | €-37.49 Million | -0.630x | +28.69% |
| 2019-12-31 | €48.08 Million | €-42.48 Million | -0.883x | -156.31% |
| 2018-12-31 | €86.62 Million | €-29.86 Million | -0.345x | -- |